2010 was truly a breakout year for Destination Therapy (DT), following FDA approval of the HeartMate II for this indication in January. Commercial utilization of HeartMate II accelerated, and clinical outcomes continued to improve.
to see the latest HeartMate II Destination Therapy data.
“The Thoratec HeartMate II has enabled us to offer mechanical circulatory support to a broader range of patients than ever before. The size and characteristics of the HMII has allowed us to treat smaller, older and sicker patients. This advanced technology has enabled them to recapture their lives and interests in an unprecedented fashion.”
Scott Silvestry, M.D.
Associate Professor of Surgery
Surgical Director
Cardiac Transplantation and Ventricular Assist Device Program
Washington University / Barnes Jewish Hospital
page 1 of 2 >